CLASS ACTION UPDATE for FREQ, RLX and DIDI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / July 19, 2021 /Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FREQ Shareholders Click Here:https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=17760&wire=1
RLX Shareholders Click Here:https://www.zlk.com/pslra-1/rlx-technology-inc-loss-submission-form?prid=17760&wire=1
DIDI Shareholders Click Here:https://www.zlk.com/pslra-1/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form?prid=17760&wire=1
* ADDITIONAL INFORMATION BELOW *
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
FREQ Lawsuit on behalf of: investors who purchased November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=17760&wire=1
According to the filed complaint, during the class period, Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
RLX Technology Inc. (NYSE:RLX)
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Lead Plaintiff Deadline: August 9, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/rlx-technology-inc-loss-submission-form?prid=17760&wire=1
According to the filed complaint, the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
Didi Global Inc. F/K/A Xiaoju Kuaizhi Inc. (NYSE:DIDI)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired DiDi: (a) American Depositary Shares pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2021 initial public offering; and/or (b) securities between June 30, 2021 and July 2, 2021, inclusive.
Lead Plaintiff Deadline: September 7, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/didi-global-inc-f-k-a-xiaoju-kuaizhi-inc-loss-submission-form?prid=17760&wire=1
According to the filed complaint, (1) DiDi's apps did not comply with applicable laws and regulations governing privacy protection and the collection of personal information; (2) as a result, the Company was reasonably likely to incur scrutiny from the Cyberspace Administration of China; (3) the CAC had already warned DiDi to delay its IPO to conduct a self-examination of its network security; (4) as a result of the foregoing, DiDi's apps were reasonably likely to be taken down from app stores in China, which would have an adverse effect on its financial results and operations; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE:Levi & Korsinsky, LLP
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.